User:Mr. Ibrahem/Pacritinib

Pacritinib, sold under the brand name Vonjo, is an medication used to treat myelofibrosis. Specifically it is used in those with a platelet count less than 50 × 109/L in who it decreases the size of the spleen. It is taken by mouth.

Common side effects include diarrhea, low platelets, nausea, low hemoglobin, and swollen legs. Other side effects may include bleeding, prolonged QT, deep vein thrombosis, cancer, and infection. Use is not recommended in those with significant liver or kidney problems. It is a kinase inhibitor that blocks the action of Janus kinase 2 (JAK2) and fms-like tyrosine kinase 3\CD135 (FLT3).

Pacritinib was approved for medical use in the United States in 2022. Its application for approval in Europe was withdrawn in 2017 due to concerns it worsened outcomes. In the United States a month of medication costs about 23,000 USD as of 2022.